These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36065929)

  • 21. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
    Rinaldi D; Assogna F; Sforza M; Tagliente S; Pontieri FE
    Neurol Sci; 2018 Jan; 39(1):141-143. PubMed ID: 28956175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: A polysomnographic rasagiline-controlled study.
    Bovenzi R; Conti M; Pierantozzi M; Testone G; Fernandes M; Manfredi N; Schirinzi T; Cerroni R; Mercuri NB; Stefani A; Liguori C
    Parkinsonism Relat Disord; 2024 Oct; 127():107103. PubMed ID: 39154406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rasagiline for the treatment of Parkinson's disease: an update.
    Stocchi F; Fossati C; Torti M
    Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
    Malmlöf T; Feltmann K; Konradsson-Geuken Å; Schneider F; Alken RG; Svensson TH; Schilström B
    J Neural Transm (Vienna); 2015 Feb; 122(2):259-72. PubMed ID: 24906468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Marconi S; Zwingers T
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
    Elmer LW; Bertoni JM
    Expert Opin Pharmacother; 2008 Nov; 9(16):2759-72. PubMed ID: 18937611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
    Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S
    Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Jost WH; Friede M; Schnitker J
    Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
    [No Abstract]   [Full Text] [Related]  

  • 40. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.